Clinical Trial Associate (CTA) Certification Exam — Questions and Answers

Question 1: In Informed Consent Process, what is the FIRST step a CTA professional should take when encountering a new case or situation?

Consult with a supervisor before taking any action
Implement an immediate solution based on past experience
Conduct a comprehensive assessment and gather all relevant information (Correct answer)
Document the situation and wait for further instructions

Correct answer: Conduct a comprehensive assessment and gather all relevant information

In Informed Consent Process, a thorough initial assessment ensures all relevant factors are identified before deciding on an appropriate course of action. This systematic approach is fundamental to Clinical Trial Associate practice.

Question 2: Which of the following best describes 'therapeutic misconception' in clinical trial research?

A participant's mistaken belief that all trial procedures are tailored to their individual medical benefit rather than to generate generalizable knowledge (Correct answer)
An investigator's false assumption that all participants fully understand the consent form
A participant's incorrect belief that the study drug has already been approved by the FDA
A sponsor's misconception that informed consent eliminates all legal liability

Correct answer: A participant's mistaken belief that all trial procedures are tailored to their individual medical benefit rather than to generate generalizable knowledge

Therapeutic misconception occurs when participants confuse the purpose of research with individualized medical treatment, compromising the voluntariness of consent.

Question 3: What is the purpose of the Trial Master File (TMF)?

To record minutes from all sponsor-investigator meetings
To store financial invoices submitted by the site for reimbursement
To archive all subject medical records post-trial
To maintain all essential documents that allow evaluation of the conduct of a trial and quality of data generated (Correct answer)

Correct answer: To maintain all essential documents that allow evaluation of the conduct of a trial and quality of data generated

The TMF contains all essential documents needed to reconstruct the trial and verify that it was conducted in compliance with GCP and regulations.

Question 4: During feasibility, a site reports 200 patients with the target diagnosis seen annually, but 80% are managed by physicians not involved in the study. How many potentially eligible patients per year should be estimated?

40 (Correct answer)
160
200
120

Correct answer: 40

Only 20% of the 200 patients (40) are managed by participating physicians and therefore realistically accessible for the study.

Question 5: Under ICH E6(R2), which party is ultimately responsible for the overall conduct, integrity, and reporting of a clinical trial?

The CRO
The Principal Investigator
The IRB/IEC
The Sponsor (Correct answer)

Correct answer: The Sponsor

The sponsor bears ultimate responsibility for the trial's overall conduct, integrity, and reporting, even when a CRO is delegated tasks.

Question 6: Which of the following events would NOT typically meet the FDA definition of a Serious Adverse Event?

A congenital anomaly in an offspring of a trial participant
Persistent significant disability affecting daily activities
A minor rash resolving within 24 hours without treatment (Correct answer)
Hospitalization for appendectomy diagnosed after enrollment

Correct answer: A minor rash resolving within 24 hours without treatment

A minor rash resolving quickly without treatment does not meet any of the seriousness criteria (death, life-threatening, hospitalization, disability, congenital anomaly, or medical significance).

Question 7: A participant enrolled in a blinded study asks the investigator to reveal their treatment assignment. What is the most appropriate response?

Transfer the participant to a different site where their assignment can be revealed
Explain that unblinding is only done for medical necessity or at study end, per protocol procedures (Correct answer)
Notify the sponsor that the participant has withdrawn consent
Immediately unblind the participant and document it as a protocol deviation

Correct answer: Explain that unblinding is only done for medical necessity or at study end, per protocol procedures

Unblinding during a trial is generally reserved for medical emergencies or as defined by the protocol, and investigators should explain this to participants.

Question 8: What is the correct action when investigational product at a site reaches its expiration date?

Quarantine the expired product, notify the sponsor, and arrange disposal per protocol (Correct answer)
Return it immediately to the manufacturer for relabeling
Continue using it until the current supply is exhausted to avoid waste
Obtain written sponsor authorization to use it beyond the expiration date

Correct answer: Quarantine the expired product, notify the sponsor, and arrange disposal per protocol

Expired IP must be quarantined and removed from use immediately; the sponsor must be notified and disposal must follow the protocol's or sponsor's destruction instructions.

Question 9: Under GCP, what action must an investigator take when a protocol deviation that may affect subject safety occurs?

Correct it without documentation to minimize regulatory burden
Wait until the monitoring visit to disclose it
Document it in the next quarterly report to the sponsor
Report it promptly to the sponsor, IRB/IEC, and regulatory authority as required (Correct answer)

Correct answer: Report it promptly to the sponsor, IRB/IEC, and regulatory authority as required

Protocol deviations affecting subject safety must be promptly reported to the sponsor, IRB/IEC, and regulatory authorities according to applicable requirements.

Question 10: According to GCP guidelines, where should investigational products be stored at a clinical trial site?

In the same refrigerator used for routine laboratory samples
In the CTA's office for easy access during participant visits
In a designated, secure area under conditions specified by the sponsor protocol (Correct answer)
In any secure location chosen by the principal investigator

Correct answer: In a designated, secure area under conditions specified by the sponsor protocol

GCP requires IP to be stored in a secure, designated area that meets the temperature, humidity, and light conditions specified by the sponsor to maintain product integrity.

Question 11: A subject is hospitalized for a planned surgical procedure that was scheduled before trial enrollment. How should this be classified?

Protocol deviation requiring IRB reporting
Adverse Drug Reaction requiring immediate sponsor notification
SAE — hospitalization always qualifies
Not an SAE if the hospitalization was pre-planned and unrelated to the trial (Correct answer)

Correct answer: Not an SAE if the hospitalization was pre-planned and unrelated to the trial

ICH E6 and most protocols exclude planned/elective hospitalizations that are unrelated to the study from SAE criteria, provided this exclusion is specified in the protocol.

Question 12: Which of the following best describes a 'protocol template' in the context of clinical trial operations?

A completed protocol approved by the FDA
A standardized framework containing required sections that can be customized for specific studies (Correct answer)
The statistical analysis plan for a specific study
A regulatory submission dossier

Correct answer: A standardized framework containing required sections that can be customized for specific studies

A protocol template is a standardized framework with required sections that sponsors use as a starting point, customizing it for each specific study.

Question 13: Why must adverse events be reported to regulatory authorities?

To allow more participant enrollment
To reduce monitoring visits
To delay study timelines
To maintain FDA approval (Correct answer)

Correct answer: To maintain FDA approval

Reporting adverse events (AEs) to regulatory authorities, such as the FDA, is a mandatory requirement for all clinical trials. This ensures that the regulatory body is continuously informed about the safety profile of the investigational product, allowing them to assess ongoing risks and make informed decisions about the drug's development. Timely and accurate reporting is essential to maintain the study's regulatory approval and ensure public safety.

Question 14: A certificate of analysis (CoA) for investigational product is filed in the TMF primarily to:

Document shipping costs
Record subject dosing schedules
Confirm that the product meets specified quality standards before dispensing (Correct answer)
Approve the site's pharmacy facilities

Correct answer: Confirm that the product meets specified quality standards before dispensing

The CoA verifies that each batch of investigational product meets pre-defined quality, potency, and purity specifications.

Question 15: A participant asks whether they can withdraw from the study at any time. Which response is most accurate according to GCP?

Withdrawal is only permitted before the first dose of study drug is administered
Participants may withdraw at any time without penalty or loss of benefits to which they are otherwise entitled (Correct answer)
Withdrawal is allowed but requires a 30-day notice period per protocol
Participants may withdraw but must complete the end-of-study visit to do so

Correct answer: Participants may withdraw at any time without penalty or loss of benefits to which they are otherwise entitled

GCP and 21 CFR 50.25(a)(8) require that participants be informed they may withdraw at any time without penalty or loss of otherwise entitled benefits.

Question 16: What is the PRIMARY purpose of continuing education requirements in Informed Consent Process for CTA professionals?

Networking with other professionals in the field
Maintaining current knowledge and competency as the field evolves (Correct answer)
Earning additional credentials for career advancement
Fulfilling mandatory regulatory requirements only

Correct answer: Maintaining current knowledge and competency as the field evolves

Continuing education in Informed Consent Process ensures professionals maintain current knowledge and skills as standards, technologies, and best practices evolve in the Clinical Trial Associate field.

Question 17: A participant enrolled in a long-term study moves to another state. They call the site and verbally revoke their consent over the phone. How should the site document this?

Contact the IRB to determine whether the verbal withdrawal is acceptable
Require the participant to return to the site to sign a formal withdrawal form before processing
No documentation is needed since verbal withdrawal is not legally binding
Document the withdrawal in the source records, note the date and method, and send a written confirmation to the participant (Correct answer)

Correct answer: Document the withdrawal in the source records, note the date and method, and send a written confirmation to the participant

Withdrawal of consent can be communicated verbally; the site must document it thoroughly in source records and may send written confirmation to the participant.

Question 18: An investigator wants to use a short-form consent document. What additional step is required beyond the participant signing the short form?

The participant must complete a comprehension quiz before signing the short form
The sponsor must approve each use of a short-form consent on a case-by-case basis
The IRB must be notified within 24 hours of each short-form consent obtained
A summary of the full consent discussion must be provided to the participant and signed by a witness (Correct answer)

Correct answer: A summary of the full consent discussion must be provided to the participant and signed by a witness

When using a short-form consent document, a written summary of what is presented orally must be given to the participant, and a witness must sign both the short form and the summary.

Question 19: In signal detection for pharmacovigilance, what is a 'signal'?

A confirmed causal relationship between a drug and an adverse event
Information from one or more sources suggesting a new or changed association between a medicine and an adverse event (Correct answer)
A notification from the FDA about a label update
An automatic alert from a clinical trial management system

Correct answer: Information from one or more sources suggesting a new or changed association between a medicine and an adverse event

A pharmacovigilance signal is information suggesting a new or changed association between a medicine and an adverse event that warrants further investigation, but does not necessarily confirm causality.

Question 20: An IRB waives the requirement for written informed consent for a minimal-risk study. Which of the following conditions must be met for this waiver?

The waiver must be renewed by the IRB every 30 days throughout the study
The study must involve only healthy volunteers with no pre-existing conditions
The sponsor must provide written approval of the waiver before the IRB grants it
The research could not practicably be carried out without the waiver and involves no more than minimal risk (Correct answer)

Correct answer: The research could not practicably be carried out without the waiver and involves no more than minimal risk

Under 21 CFR 56.109(c) and 45 CFR 46.117(c), IRBs may waive written consent when the research involves minimal risk and cannot practicably be conducted otherwise.

Question 21: When a subject withdraws from a clinical trial, the CRF should:

Be left incomplete with no further notation
Be destroyed to protect the subject's privacy
Document the withdrawal date, reason for withdrawal, and last known data points, then close the subject record appropriately (Correct answer)
Have all previously entered data deleted per HIPAA requirements

Correct answer: Document the withdrawal date, reason for withdrawal, and last known data points, then close the subject record appropriately

Withdrawal must be documented with the date, reason, and final data points; previously collected data is retained per the protocol and regulatory requirements unless the subject specifically requests data deletion (where permitted).

Question 22: What does the term 'capacity' mean in the context of informed consent?

The legal age threshold set by each state for medical decision-making
The physical ability of a participant to complete all study visits
A participant's ability to understand information, appreciate its relevance, reason about options, and communicate a choice (Correct answer)
The maximum number of participants a site is authorized to enroll

Correct answer: A participant's ability to understand information, appreciate its relevance, reason about options, and communicate a choice

Capacity refers to the cognitive and communicative ability to make an informed voluntary decision, distinct from legal competence.

Question 23: A participant signs the consent form but later tells a nurse they did not understand what they signed. What is the most appropriate action?

Re-conduct the consent discussion to ensure comprehension, answer all questions, and have the participant re-sign if they still wish to participate (Correct answer)
Document the statement in the medical record and continue without further intervention
Reassure the participant and proceed since the signature is legally binding
Withdraw the participant from the study immediately without further discussion

Correct answer: Re-conduct the consent discussion to ensure comprehension, answer all questions, and have the participant re-sign if they still wish to participate

Informed consent is an ongoing process; if a participant indicates they did not understand, the consent discussion must be repeated and comprehension verified before continued participation.

Question 24: Which of the following scenarios represents a breach of informed consent documentation requirements under FDA regulations?

The consent form is stored in a locked file cabinet at the site
The consent form is signed after a study-related blood draw has already been performed (Correct answer)
The consent form includes a statement about compensation for injury
The consent form is printed in 12-point font

Correct answer: The consent form is signed after a study-related blood draw has already been performed

Performing any study-related procedure before obtaining signed informed consent violates 21 CFR 50.20, which requires consent prior to trial participation.

Question 25: What is the primary purpose of the 'cooling-off' period sometimes allowed between consent and enrollment?

To give participants time to reconsider their decision and consult with others before committing (Correct answer)
To ensure the investigator has completed all required training
To allow the IRB to verify the participant's eligibility criteria
To allow the sponsor to review the consent form before the participant signs

Correct answer: To give participants time to reconsider their decision and consult with others before committing

A cooling-off period gives participants adequate time to reflect on their decision and discuss participation with family or advisors without pressure.

Question 26: When a conflict arises between standard procedures and a unique situation in Data Collection & CRF Management, what should a CTA professional prioritize?

The preference of the client or stakeholder
Safety and ethical obligations while seeking expert consultation (Correct answer)
Strict adherence to written procedures without exception
The most cost-effective solution available

Correct answer: Safety and ethical obligations while seeking expert consultation

Safety and ethics always take priority in Data Collection & CRF Management. When standard procedures don't adequately address a unique situation, consulting with experienced colleagues or supervisors ensures both safety and professional standards are maintained.

Question 27: What does 'blinding' refer to in the context of randomized controlled trials?

Preventing site staff from viewing the study protocol
Encrypting subject identifiers in the database
Withholding knowledge of treatment assignment from participants and/or investigators (Correct answer)
Restricting data access to the biostatistics team only

Correct answer: Withholding knowledge of treatment assignment from participants and/or investigators

Blinding (masking) is a procedure where knowledge of the treatment assignment is withheld from subjects, investigators, or both to reduce bias.

Question 28: Which of the following is NOT typically included in the Trial Master File (TMF) at the sponsor level?

Regulatory agency correspondence
Subject medical histories and source records (Correct answer)
Signed investigator agreements
IRB approval letters

Correct answer: Subject medical histories and source records

Subject medical histories and source records are confidential documents held at the site, not in the sponsor's TMF.

Question 29: A sponsor's CRF data cut reveals that 15% of subjects have missing 'prior medication' data. What is the MOST appropriate corrective action?

Issue targeted queries to all affected sites requesting completion or explanation of missing data (Correct answer)
Carry forward the last known medication data for statistical analysis
Remove those subjects from the intent-to-treat population
Report the missing data to the FDA as a protocol deviation

Correct answer: Issue targeted queries to all affected sites requesting completion or explanation of missing data

Missing CRF data should be addressed through queries to the originating sites, requesting either completion of the missing information or a documented reason (e.g., 'not collected').

Question 30: When a subject withdraws from a trial, which documentation step is mandatory at the site?

Destroy all source documents related to that subject
Record the withdrawal date, reason if given, and any follow-up per protocol (Correct answer)
File an SAE report automatically
Remove the subject from all listings retroactively

Correct answer: Record the withdrawal date, reason if given, and any follow-up per protocol

Subject withdrawal must be documented with date, reason (if volunteered), and any safety follow-up required by the protocol.

Question 31: A sponsor transfers all monitoring responsibilities to a CRO. According to ICH E6(R2), what responsibility does the sponsor retain?

Only financial responsibility for the trial
No responsibilities — CRO assumes full liability
Oversight of the CRO's performance of those responsibilities (Correct answer)
Responsibility for IRB approvals only

Correct answer: Oversight of the CRO's performance of those responsibilities

Even when a sponsor transfers trial-related duties to a CRO, ICH E6(R2) requires the sponsor to retain ultimate responsibility and oversight of the CRO.

Question 32: What is the CTA's responsibility when a monitoring visit report identifies an action item requiring site response?

Review the report, implement corrective actions within the specified timeframe, and document the response (Correct answer)
Ignore action items that relate to issues already corrected
File the report without review since the CRA handles all follow-up
Forward the report to the IRB for resolution

Correct answer: Review the report, implement corrective actions within the specified timeframe, and document the response

CTAs must review monitoring reports, take corrective actions promptly within specified timelines, and document all responses to close each action item.

Question 33: A prospective participant is in an acute pain crisis when approached for consent to a pain management trial. Which concern does this raise?

Pain may impair voluntary decision-making and comprehension, raising questions about the validity of consent obtained in this state (Correct answer)
Consent is valid as long as the participant signs the form regardless of their current condition
Acute pain disqualifies a participant from all clinical trials by regulation
The investigator must obtain IRB approval before speaking to any participant in pain

Correct answer: Pain may impair voluntary decision-making and comprehension, raising questions about the validity of consent obtained in this state

Acute distress or pain can compromise a person's ability to make a truly voluntary and fully informed decision, so consent obtained under these conditions may be ethically questionable.

Question 34: What is the key difference between a 'protocol violation' and a 'protocol deviation'?

Protocol violations involve billing errors; deviations involve data errors
Protocol violations are intentional departures; deviations are unintentional
Protocol violations are serious departures that may affect subject safety or data integrity; deviations are minor departures (Correct answer)
There is no difference—they are interchangeable terms

Correct answer: Protocol violations are serious departures that may affect subject safety or data integrity; deviations are minor departures

Protocol violations are serious departures from the protocol that may affect subject rights, safety, or data integrity, while deviations are minor unintended departures.

Question 35: What is the role of an impartial witness during the informed consent process?

To translate the consent form into the participant's native language
To countersign the form on behalf of the IRB as the oversight representative
To verify that the participant meets the protocol's inclusion and exclusion criteria
To attest that the information was accurately explained and that the participant voluntarily signed the consent form (Correct answer)

Correct answer: To attest that the information was accurately explained and that the participant voluntarily signed the consent form

An impartial witness attests that the consent information was presented accurately and that the participant's consent was voluntary, serving as an independent verification of the process.

Question 36: What should be done if a GCP violation occurs during a trial?

Notify media
Report and document the incident (Correct answer)
Continue without action
Ignore if minor

Correct answer: Report and document the incident

Any GCP violation, regardless of perceived severity, must be promptly reported and thoroughly documented. This process ensures transparency, allows for investigation into the root cause, and enables corrective and preventive actions to be implemented. Proper reporting is essential for maintaining trial integrity, protecting subject safety, and demonstrating compliance to regulatory authorities.

Question 37: A site delegation log (Signature and Delegation Log) documents:

IRB membership roster
Drug shipment receipt dates
Staff qualifications and trial tasks delegated by the PI to sub-investigators and coordinators (Correct answer)
Sponsor approvals for protocol amendments

Correct answer: Staff qualifications and trial tasks delegated by the PI to sub-investigators and coordinators

The delegation log shows which qualified personnel have been assigned specific trial responsibilities by the principal investigator.

Question 38: What is the purpose of a Protocol Deviation Report (PDR) in a clinical trial?

To terminate a subject's participation in the trial
To document and communicate any departure from the approved protocol (Correct answer)
To notify the IRB of a new investigator joining the site
To request a protocol amendment from the sponsor

Correct answer: To document and communicate any departure from the approved protocol

A PDR documents and communicates any departure from the approved protocol to the sponsor and, when required, to the IRB/ethics committee.

Question 39: When a conflict arises between standard procedures and a unique situation in Regulatory Submissions & Approvals, what should a CTA professional prioritize?

Safety and ethical obligations while seeking expert consultation (Correct answer)
The preference of the client or stakeholder
Strict adherence to written procedures without exception
The most cost-effective solution available

Correct answer: Safety and ethical obligations while seeking expert consultation

Safety and ethics always take priority in Regulatory Submissions & Approvals. When standard procedures don't adequately address a unique situation, consulting with experienced colleagues or supervisors ensures both safety and professional standards are maintained.

Question 40: When a conflict arises between standard procedures and a unique situation in Informed Consent Process, what should a CTA professional prioritize?

Strict adherence to written procedures without exception
Safety and ethical obligations while seeking expert consultation (Correct answer)
The most cost-effective solution available
The preference of the client or stakeholder

Correct answer: Safety and ethical obligations while seeking expert consultation

Safety and ethics always take priority in Informed Consent Process. When standard procedures don't adequately address a unique situation, consulting with experienced colleagues or supervisors ensures both safety and professional standards are maintained.

Question 41: What documentation practice is considered essential in Informed Consent Process within the Clinical Trial Associate field?

Only documenting unusual events or complications
Using shorthand notes that can be expanded later if needed
Completing all documentation at the end of the workday
Recording actions, observations, and outcomes in real-time or as close to the event as possible (Correct answer)

Correct answer: Recording actions, observations, and outcomes in real-time or as close to the event as possible

Real-time or near-real-time documentation in Informed Consent Process ensures accuracy, provides a contemporaneous record, and is considered the gold standard for professional accountability and legal defensibility.

Question 42: Who is responsible for maintaining accurate and timely documentation at the study site?

Clinical Research Organization
FDA
Trial sponsor
Principal Investigator (Correct answer)

Correct answer: Principal Investigator

The Principal Investigator (PI) at the study site bears ultimate responsibility for the conduct of the clinical trial, including ensuring the accuracy, completeness, and timeliness of all documentation. This encompasses overseeing data collection, maintaining source documents, and ensuring compliance with the protocol, Good Clinical Practice (GCP), and regulatory requirements. The PI's oversight is fundamental to the integrity of the study data and participant safety.

Question 43: Under 21 CFR Part 312, how long must an investigator retain essential trial documents after the study is completed or discontinued?

Indefinitely
2 years after NDA approval or 2 years after the investigation is discontinued (Correct answer)
5 years after study completion
1 year after study closure

Correct answer: 2 years after NDA approval or 2 years after the investigation is discontinued

21 CFR 312.62 requires investigators to retain records for 2 years after the FDA approves a marketing application or 2 years after the study is discontinued.

Question 44: What is a Certificate of Analysis (CoA) for investigational products and why is it important?

A site certificate confirming all staff are trained to handle the investigational product
An IRB certificate confirming the trial protocol was analyzed and approved
A financial document confirming the sponsor paid for the drug batch
A document from the manufacturer certifying that a specific IP lot meets defined quality specifications (Correct answer)

Correct answer: A document from the manufacturer certifying that a specific IP lot meets defined quality specifications

A CoA issued by the manufacturer confirms that the specific IP lot was tested and meets all quality, purity, and potency specifications, providing documentation of product integrity before use in participants.

Question 45: Under 21 CFR Part 312, how long must an investigator retain clinical trial records after the investigation is discontinued or completed?

1 year
2 years (Correct answer)
10 years
5 years

Correct answer: 2 years

Under 21 CFR 312.62, investigators must retain records for at least 2 years after the date on which a marketing application is approved, or 2 years after the investigation is discontinued.

Question 46: What action should a CTA take if they discover that an SAE was not reported within the required timeframe?

Instruct the site to back-date the report
Amend the protocol to extend reporting timelines
Wait until the next monitoring visit to address it
Immediately notify the sponsor and document the deviation (Correct answer)

Correct answer: Immediately notify the sponsor and document the deviation

A late SAE report is a protocol deviation that must be immediately escalated to the sponsor and fully documented to ensure transparency and regulatory compliance.

Question 47: Which document must a sponsor maintain that lists all investigators authorized to conduct the clinical trial under an IND?

Form FDA 3500A
Form FDA 1572 (Statement of Investigator) (Correct answer)
Form FDA 2253
Form FDA 356h

Correct answer: Form FDA 1572 (Statement of Investigator)

FDA Form 1572 is signed by each investigator and describes their qualifications, commitments, and the study site, and is maintained in the IND.

Question 48: A subject withdraws consent mid-study and requests that all data collected be destroyed. Under ICH GCP and US regulations, what is the correct response?

The IRB must approve data destruction within 48 hours
All data must be destroyed immediately to respect the subject's rights
Data already entered into the CRF may be retained, but no further data will be collected (Correct answer)
The sponsor may continue collecting data without the subject's participation

Correct answer: Data already entered into the CRF may be retained, but no further data will be collected

Under GCP, a subject may withdraw consent for future data collection, but data already recorded may be retained for trial integrity and safety purposes unless local law requires otherwise.

Question 49: How does risk management apply to daily practice in Site Management & Monitoring for Clinical Trial Associate professionals?

Through annual safety audits exclusively
Only through responding to incidents after they occur
Through proactive identification of potential hazards and implementation of preventive measures (Correct answer)
By avoiding high-risk situations entirely

Correct answer: Through proactive identification of potential hazards and implementation of preventive measures

Effective risk management in Site Management & Monitoring requires proactive hazard identification and preventive measures, not just reactive responses. This approach reduces incidents, improves outcomes, and protects both professionals and clients.

Question 50: Under 21 CFR Part 50, which of the following constitutes a required element of informed consent?

The expected number of publications resulting from the study
The names of all IRB members who reviewed the protocol
A description of any reasonably foreseeable risks or discomforts (Correct answer)
The total cost of the study drug to the sponsor

Correct answer: A description of any reasonably foreseeable risks or discomforts

21 CFR 50.25(a)(2) requires disclosure of reasonably foreseeable risks or discomforts as a basic element of informed consent.

Question 51: Which document at the site level serves as the primary source for tracking and reconciling all reported adverse events?

The Drug Accountability Log
The Adverse Event Log (AE Log) (Correct answer)
The Delegation Log
The Investigator Brochure

Correct answer: The Adverse Event Log (AE Log)

The Adverse Event Log is the site-level source document used to capture, track, and reconcile all AEs and SAEs throughout the trial.

Question 52: When obtaining consent from a non-English speaking participant, which approach is compliant with FDA requirements?

Obtain consent in English since FDA regulations require English-language consent forms
Use the short-form process only, regardless of the availability of translated materials
Use an IRB-approved translated consent form in the participant's language, with a qualified interpreter if needed (Correct answer)
Have a bilingual family member translate the English consent form verbally without written translation

Correct answer: Use an IRB-approved translated consent form in the participant's language, with a qualified interpreter if needed

The FDA requires that consent information be presented in language understandable to the participant; IRB-approved translations or the short-form process with a qualified interpreter are acceptable approaches.

Question 53: What should be done if a data entry error is found in a CRF?

Ignore it
Send it to the sponsor for editing
Erase and overwrite it
Correct it, date it, and explain the change (Correct answer)

Correct answer: Correct it, date it, and explain the change

When a data entry error is found in a CRF, it must be corrected in a way that maintains an audit trail and ensures data integrity. The correct procedure involves drawing a single line through the incorrect entry, writing the correct information, dating the change, and initialing it, often with a brief explanation for the modification. This ensures the original entry remains legible and the change is transparent and attributable.

Question 54: When a sponsor issues a new version of a protocol, how is version control typically managed in the document?

A version history table documents each version number, date, and summary of changes (Correct answer)
Versions are tracked verbally during investigator meetings only
The FDA maintains a central registry of all protocol versions
Only the most recent version is kept; prior versions are destroyed

Correct answer: A version history table documents each version number, date, and summary of changes

Protocols use a version history table to document each revision, including version number, date of revision, and a summary of changes made.

Question 55: A participant signs the consent form but then asks the study coordinator not to tell their spouse about their participation. How should the coordinator respond?

Inform the participant that while their records are confidential, their personal health disclosures are their own choice (Correct answer)
Refuse enrollment since confidentiality cannot be guaranteed to the spouse
Contact the IRB immediately to report the participant's request
Document the spouse as a legally authorized representative in the study records

Correct answer: Inform the participant that while their records are confidential, their personal health disclosures are their own choice

Confidentiality of study records is maintained by the research team; what participants share personally is their own decision.

Question 56: A sponsor's feasibility team identifies two candidate sites with similar patient populations. Site A has a dedicated research nurse; Site B does not. Which factor does this MOST directly affect?

Protocol complexity tolerance
Investigator's conflict-of-interest disclosure
Operational capacity and subject management quality (Correct answer)
Site's regulatory submission timeline

Correct answer: Operational capacity and subject management quality

A dedicated research nurse directly improves subject recruitment, scheduling, data collection, and overall operational capacity.

Question 57: Which section of the ICH E6(R2) guideline specifically addresses the content and maintenance of the Investigator's Site File (ISF)?

Section 8 — Essential Documents (Correct answer)
Section 4 — Investigator
Section 6 — Clinical Trial Protocol
Section 5 — Sponsor

Correct answer: Section 8 — Essential Documents

Section 8 of ICH E6(R2) covers essential documents, cataloguing what must be maintained in both the investigator's and sponsor's trial master files.

Question 58: A sponsor-employed nurse conducts the informed consent discussion for a trial at an investigative site. What is the key concern with this arrangement?

The participant may feel undue pressure to enroll because the nurse represents the entity funding the trial (Correct answer)
It violates GCP because only physicians may obtain consent
Nurses are not qualified to explain clinical trial procedures
The sponsor nurse cannot be listed on the consent form as the person who explained the study

Correct answer: The participant may feel undue pressure to enroll because the nurse represents the entity funding the trial

Sponsor employees obtaining consent may create a conflict of interest and undue influence, as participants may feel obligated to enroll to please the funding source.

Question 59: A site is using an electronic health record (EHR) to capture source data for a clinical trial. Under 21 CFR Part 11, the EHR system must:

Convert all data to paper format before submission to the sponsor
Be approved by the FDA before any data can be captured
Meet requirements for electronic records and signatures, including audit trails and access controls (Correct answer)
Print all records daily to maintain paper backups only

Correct answer: Meet requirements for electronic records and signatures, including audit trails and access controls

21 CFR Part 11 requires electronic systems used in FDA-regulated trials to have audit trails, access controls, and validated processes ensuring data integrity.

Question 60: Which document is used to record data collected from each participant in a trial?

Monitoring Log
Informed Consent Form
Site Master File
Case Report Form (CRF) (Correct answer)

Correct answer: Case Report Form (CRF)

A Case Report Form (CRF) is a paper or electronic document specifically designed to record all protocol-required information collected from each participant in a clinical trial. It serves as the primary data collection tool, ensuring standardized and systematic capture of participant demographics, medical history, treatment details, adverse events, and efficacy measurements. The CRF is critical for data integrity and analysis.

Question 61: Which component of a protocol ensures continuity of care if a participant is discontinued from the study?

Drug accountability procedures
Randomization procedures
Washout period specifications
Discontinuation and withdrawal criteria section (Correct answer)

Correct answer: Discontinuation and withdrawal criteria section

The discontinuation and withdrawal criteria section outlines procedures for safely removing participants and ensuring appropriate follow-up care.

Question 62: What is the FDA's MedWatch program?

An FDA initiative to educate clinical investigators
The FDA's safety information and adverse event reporting program for marketed medical products (Correct answer)
A drug approval tracking system for sponsors
A program to monitor clinical trial site compliance

Correct answer: The FDA's safety information and adverse event reporting program for marketed medical products

MedWatch is the FDA's Safety Information and Adverse Event Reporting Program that allows healthcare professionals and the public to report serious adverse events associated with marketed drugs, biologics, and devices.

Question 63: Why is it important to follow standard operating procedures (SOPs)?

To skip protocol approvals
To reduce sponsor responsibilities
To ensure consistent and compliant trial conduct (Correct answer)
To shorten the trial timeline

Correct answer: To ensure consistent and compliant trial conduct

Standard Operating Procedures (SOPs) are detailed, written instructions that describe how to perform routine tasks and processes within a clinical trial. Following SOPs is crucial because it ensures consistency, quality, and compliance with GCP and regulatory requirements across all trial activities. This standardization minimizes variability and helps maintain the integrity and reliability of trial data.

Question 64: A participant experiences a serious adverse event (SAE) mid-trial that is identified as a new risk. How does this affect the informed consent process?

The sponsor must halt the trial until all participants provide new consent
No action is needed since the participant already signed the original consent form
The IRB must be notified and may require a consent form amendment; currently enrolled participants may need to be reconsented (Correct answer)
The site must withdraw the participant from the trial until the SAE is resolved

Correct answer: The IRB must be notified and may require a consent form amendment; currently enrolled participants may need to be reconsented

New safety information that may affect participant willingness must be reported to the IRB, which may require a consent amendment and reconsent of enrolled participants.

Question 65: In a double-blind randomized controlled trial, the 'blind' is considered 'broken' when:

The sponsor conducts an interim analysis
A subject withdraws consent from the trial
The trial reaches its target enrollment number
The treatment assignment of a subject is revealed before unblinding (Correct answer)

Correct answer: The treatment assignment of a subject is revealed before unblinding

An unplanned revelation of a subject's treatment assignment before the protocol-specified unblinding date constitutes a protocol deviation known as an unblinding or broken blind.

Question 66: In Good Clinical Practice & ICH Guidelines, what is the FIRST step a CTA professional should take when encountering a new case or situation?

Document the situation and wait for further instructions
Implement an immediate solution based on past experience
Consult with a supervisor before taking any action
Conduct a comprehensive assessment and gather all relevant information (Correct answer)

Correct answer: Conduct a comprehensive assessment and gather all relevant information

In Good Clinical Practice & ICH Guidelines, a thorough initial assessment ensures all relevant factors are identified before deciding on an appropriate course of action. This systematic approach is fundamental to Clinical Trial Associate practice.

Question 67: When must an investigator notify the sponsor of a protocol deviation?

Within the timeframe specified in the protocol or monitoring plan (Correct answer)
Only at study close-out
Annually during audit preparation
Only if the deviation affects a primary endpoint

Correct answer: Within the timeframe specified in the protocol or monitoring plan

Protocol and monitoring plan requirements dictate the notification timeline so sponsors can assess impact and take corrective action.

Question 68: A site uses both paper CRFs and an electronic data capture system for the same study. This hybrid approach requires:

Clear procedures specifying which system is the source record to avoid duplicate or conflicting data (Correct answer)
IRB approval before switching to eCRF mid-study
Separate informed consent forms for paper versus electronic data collection
All paper CRFs to be destroyed once data is entered electronically

Correct answer: Clear procedures specifying which system is the source record to avoid duplicate or conflicting data

Hybrid data collection requires unambiguous procedures identifying which record is the source to prevent conflicting data and ensure a clear audit trail.

Question 69: Who must authorize any changes to investigational product storage conditions at a clinical trial site?

The local pharmacy board in the state where the site is located
The site's principal investigator acting alone
The sponsor or designee, typically in writing before implementation (Correct answer)
The CTA or study coordinator managing daily operations

Correct answer: The sponsor or designee, typically in writing before implementation

Storage condition changes must be pre-approved by the sponsor in writing because the sponsor is responsible for maintaining IP quality and any deviation requires formal authorization to ensure regulatory compliance.

Question 70: Which ICH guideline specifically governs Good Clinical Practice standards for the design, conduct, and monitoring of clinical trials?

ICH E9
ICH E8
ICH Q10
ICH E6(R2) (Correct answer)

Correct answer: ICH E6(R2)

ICH E6(R2) is the internationally recognized GCP guideline covering all aspects of clinical trial conduct, including monitoring, documentation, and quality standards.

Question 71: Which scenario would trigger an IND safety report (IND Annual Report supplement) requirement under 21 CFR Part 312.32?

An approved protocol amendment is implemented
A site coordinator changes employment
A subject misses a scheduled clinic visit
An unexpected fatal serious adverse event reasonably related to the investigational drug (Correct answer)

Correct answer: An unexpected fatal serious adverse event reasonably related to the investigational drug

Under 21 CFR Part 312.32, sponsors must submit expedited IND safety reports for unexpected fatal or life-threatening serious adverse drug reactions.

Question 72: Which element is classified as an 'additional' rather than 'basic' element of informed consent under 21 CFR 50.25?

The expected duration of the participant's involvement
A description of the procedures to be followed
A statement that significant new findings will be disclosed to participants (Correct answer)
A description of reasonably foreseeable risks

Correct answer: A statement that significant new findings will be disclosed to participants

Under 21 CFR 50.25(b), disclosing significant new findings that may affect willingness to continue is an additional element, not a required basic element.

Question 73: What is the PRIMARY purpose of continuing education requirements in Good Clinical Practice & ICH Guidelines for CTA professionals?

Earning additional credentials for career advancement
Fulfilling mandatory regulatory requirements only
Maintaining current knowledge and competency as the field evolves (Correct answer)
Networking with other professionals in the field

Correct answer: Maintaining current knowledge and competency as the field evolves

Continuing education in Good Clinical Practice & ICH Guidelines ensures professionals maintain current knowledge and skills as standards, technologies, and best practices evolve in the Clinical Trial Associate field.

Question 74: How does risk management apply to daily practice in Adverse Event Reporting for Clinical Trial Associate professionals?

Through annual safety audits exclusively
Only through responding to incidents after they occur
Through proactive identification of potential hazards and implementation of preventive measures (Correct answer)
By avoiding high-risk situations entirely

Correct answer: Through proactive identification of potential hazards and implementation of preventive measures

Effective risk management in Adverse Event Reporting requires proactive hazard identification and preventive measures, not just reactive responses. This approach reduces incidents, improves outcomes, and protects both professionals and clients.

Question 75: What is the primary function of a global safety database in pharmacovigilance?

To archive regulatory correspondence with health authorities
To collect, manage, and report all individual case safety reports (ICSRs) for a product (Correct answer)
To store financial data about drug development costs
To track clinical trial enrollment milestones

Correct answer: To collect, manage, and report all individual case safety reports (ICSRs) for a product

A global safety database centralizes all individual case safety reports received for a product, enabling aggregate analysis, signal detection, and regulatory reporting.

Question 76: What documentation practice is considered essential in Study Startup & Feasibility within the Clinical Trial Associate field?

Only documenting unusual events or complications
Using shorthand notes that can be expanded later if needed
Completing all documentation at the end of the workday
Recording actions, observations, and outcomes in real-time or as close to the event as possible (Correct answer)

Correct answer: Recording actions, observations, and outcomes in real-time or as close to the event as possible

Real-time or near-real-time documentation in Study Startup & Feasibility ensures accuracy, provides a contemporaneous record, and is considered the gold standard for professional accountability and legal defensibility.

Question 77: What is the correct procedure when an error is discovered in a paper CRF?

Use correction fluid to cover the error and write the correct value
Draw a single line through the error, write the correction, date, and initial (Correct answer)
Discard the page and start a new one
Leave the error and attach a sticky note

Correct answer: Draw a single line through the error, write the correction, date, and initial

GCP requires that corrections in paper CRFs preserve the original entry by using a single strikethrough with the corrector's initials and date.

Question 78: A CTA notices that the IRB-approved consent form version used at the site is six months out of date. What is the most appropriate immediate action?

Continue using the old form until the next monitoring visit
Notify the investigator immediately so that the current IRB-approved version can be implemented and affected participants can be reconsented (Correct answer)
Have the site update the date on the old form to make it appear current
Request a protocol deviation waiver from the sponsor

Correct answer: Notify the investigator immediately so that the current IRB-approved version can be implemented and affected participants can be reconsented

Using an outdated consent form is a protocol deviation; the site must switch to the current IRB-approved version immediately and reconsent participants if required.

Question 79: What is the purpose of including a statement about confidentiality limits in the informed consent form?

To inform participants that regulatory authorities and sponsors may inspect records, limiting absolute confidentiality (Correct answer)
To notify participants that their physician will receive all study results
To satisfy insurance company requirements for trial coverage
To warn participants that their data may be sold to third-party marketers

Correct answer: To inform participants that regulatory authorities and sponsors may inspect records, limiting absolute confidentiality

Participants must be told that while confidentiality will be maintained, records may be inspected by the FDA, sponsor, and IRB, so absolute privacy cannot be guaranteed.

Question 80: A participant who is illiterate wants to enroll in a clinical trial. Which approach is acceptable for obtaining informed consent?

Have the participant sign an X and have a witness sign attesting to the verbal consent process (Correct answer)
Obtain only verbal consent and document it in the medical record without a signature
Skip the consent form since the participant cannot read it
Allow a family member to sign the consent form on the participant's behalf without witness

Correct answer: Have the participant sign an X and have a witness sign attesting to the verbal consent process

For illiterate participants, an impartial witness must be present during the entire consent process and sign the form along with the participant's mark.

Question 81: Which study design follows a group of participants over time to assess outcomes?

Cohort study (Correct answer)
Case-control study
Ecological study
Cross-sectional study

Correct answer: Cohort study

A cohort study follows a defined group of people (a cohort) over time to observe outcomes, making it effective for studying incidence and causality.

Question 82: A site initiation visit (SIV) checklist item states that the delegation of authority log must be completed. Who is responsible for signing this log?

The CTA/CRA on behalf of the sponsor
The IRB chairperson
The institutional compliance officer
The Principal Investigator (Correct answer)

Correct answer: The Principal Investigator

The Principal Investigator must sign the delegation log to formally delegate tasks to qualified study team members.

Question 83: What is the difference between an Adverse Event (AE) and a Treatment-Emergent Adverse Event (TEAE)?

A TEAE is an AE that was absent at baseline or worsened after study treatment began (Correct answer)
TEAEs require expedited reporting while AEs do not
AEs are always more serious than TEAEs
TEAEs occur only during the washout period

Correct answer: A TEAE is an AE that was absent at baseline or worsened after study treatment began

A Treatment-Emergent Adverse Event (TEAE) is any AE that was not present before administration of the study drug or that worsened in severity after treatment initiation.

Question 84: Which document serves as the primary reference for acceptable laboratory values and normal ranges at a clinical trial site?

The Investigator's Brochure
The sponsor's standard operating procedures
The site's certified laboratory reference ranges (Correct answer)
The ICH E6 guideline

Correct answer: The site's certified laboratory reference ranges

The site's certified laboratory normal ranges are used to evaluate whether subject laboratory values are within acceptable limits.

Question 85: When a conflict arises between standard procedures and a unique situation in Protocol Development & Review, what should a CTA professional prioritize?

Strict adherence to written procedures without exception
The most cost-effective solution available
The preference of the client or stakeholder
Safety and ethical obligations while seeking expert consultation (Correct answer)

Correct answer: Safety and ethical obligations while seeking expert consultation

Safety and ethics always take priority in Protocol Development & Review. When standard procedures don't adequately address a unique situation, consulting with experienced colleagues or supervisors ensures both safety and professional standards are maintained.

Question 86: What does causality assessment in pharmacovigilance determine?

The dose at which an adverse event is most likely to occur
The likelihood that a drug caused a reported adverse event (Correct answer)
The severity classification of an adverse event
The number of patients affected by a drug interaction

Correct answer: The likelihood that a drug caused a reported adverse event

Causality assessment evaluates the likelihood of a causal relationship between a drug exposure and an adverse event, using algorithms or expert judgment to classify the relationship.

Question 87: In a protocol's schedule of events (SoE), what information is typically presented?

The IRB approval history for the protocol
Financial agreements between the sponsor and investigator
A list of all enrolled subjects and their contact information
A matrix showing all study visits, timepoints, and assessments to be performed at each visit (Correct answer)

Correct answer: A matrix showing all study visits, timepoints, and assessments to be performed at each visit

The Schedule of Events is a matrix that maps all study visits and timepoints against the assessments and procedures required at each visit.

Question 88: What is the timeframe for reporting a fatal or life-threatening unexpected SUSAR to the FDA under IND regulations?

45 calendar days
15 calendar days
30 calendar days
7 calendar days (Correct answer)

Correct answer: 7 calendar days

Under 21 CFR 312.32, fatal or life-threatening unexpected SUSARs must be reported to the FDA within 7 calendar days of the sponsor's initial receipt of the information.

Question 89: A sponsor implements a remote monitoring strategy using electronic data capture (EDC). Which GCP principle must still be upheld regardless of monitoring method?

All monitoring must be performed on-site at least quarterly
The IRB must approve each remote monitoring session
The sponsor must ensure data accuracy, completeness, and subject protection (Correct answer)
Remote monitoring eliminates the need for a monitoring plan

Correct answer: The sponsor must ensure data accuracy, completeness, and subject protection

Regardless of whether monitoring is remote or on-site, the sponsor remains responsible for ensuring subject protection and data quality per ICH E6(R2).

Question 90: What does 'unexpected' mean in the context of a Suspected Unexpected Serious Adverse Reaction (SUSAR)?

The adverse reaction was reported at only one study site
The adverse reaction is not consistent in nature or severity with the Investigator's Brochure or product labeling (Correct answer)
The adverse reaction was not anticipated by the investigator
The adverse reaction occurred in fewer than 1% of participants

Correct answer: The adverse reaction is not consistent in nature or severity with the Investigator's Brochure or product labeling

An adverse reaction is considered unexpected when its nature, severity, or frequency is not consistent with or not listed in the current Investigator's Brochure or approved product labeling.

Question 91: What does a CAPA (Corrective and Preventive Action) plan address in the context of site monitoring?

Strategies to accelerate subject enrollment
Financial reimbursements to subjects for study participation
The schedule for routine monitoring visits
Actions taken to correct identified deficiencies and prevent recurrence of protocol or GCP violations (Correct answer)

Correct answer: Actions taken to correct identified deficiencies and prevent recurrence of protocol or GCP violations

A CAPA addresses root causes of identified problems and establishes actions to prevent recurrence, a core component of clinical trial quality management.

Question 92: Which regulation governs the protection of human research subjects and requires IRB review for federally funded studies in the US?

21 CFR Part 11
21 CFR Part 312
45 CFR Part 164
45 CFR Part 46 (Correct answer)

Correct answer: 45 CFR Part 46

45 CFR Part 46 (the Common Rule) establishes requirements for IRB review and informed consent protections for federally funded human subjects research.

Question 93: A sponsor-investigator is best defined as an individual who:

Both initiates and conducts the clinical investigation (Correct answer)
Reviews protocols on behalf of the FDA
Manages IRB submissions for academic institutions
Monitors trials on behalf of a pharmaceutical company

Correct answer: Both initiates and conducts the clinical investigation

A sponsor-investigator is an individual who both initiates and actually conducts a clinical investigation, taking on the combined responsibilities of sponsor and investigator.

Question 94: A clinical trial uses a blind assessment design. During a monitoring visit, the CRA notices the randomization code has been broken for one subject. What should the CRA document this as?

An unplanned unblinding, which is a protocol deviation requiring documentation and sponsor notification (Correct answer)
A serious adverse event
A data query to be resolved by the data manager
A routine event requiring no action

Correct answer: An unplanned unblinding, which is a protocol deviation requiring documentation and sponsor notification

Unplanned unblinding is a protocol deviation that must be documented, reported to the sponsor, and assessed for its impact on data integrity and subject safety.

Question 95: A protocol amendment requiring prior FDA approval before implementation would most likely involve:

An updated version of the investigator's CV
An increase in radiation exposure to subjects (Correct answer)
Addition of a new investigational site in the same country
A change in the study coordinator's contact information

Correct answer: An increase in radiation exposure to subjects

Amendments that increase risk to subjects, such as increased radiation exposure, require FDA approval before implementation.

Question 96: What is the significance of the Belmont Report's principle of 'respect for persons' to the informed consent process?

It requires that all consent forms be written at a sixth-grade reading level
It requires that all participants receive monetary compensation for their time
It mandates that individuals be treated as autonomous agents and that those with diminished autonomy receive special protections (Correct answer)
It prohibits the enrollment of any vulnerable populations in clinical trials

Correct answer: It mandates that individuals be treated as autonomous agents and that those with diminished autonomy receive special protections

Respect for persons requires acknowledging individual autonomy and providing additional protections for those with diminished capacity, forming the ethical basis for informed consent.

Question 97: What is the primary purpose of a drug accountability binder maintained at a clinical trial site?

To provide a centralized, auditable record of all IP transactions including receipts, dispensing, returns, and destruction (Correct answer)
To file the sponsor's investigational new drug application supporting documents
To record financial payments made to participants for study drug costs
To store participant medical records alongside dispensing records

Correct answer: To provide a centralized, auditable record of all IP transactions including receipts, dispensing, returns, and destruction

The drug accountability binder consolidates all IP transaction records in one location, enabling auditors and monitors to verify that all product is fully accounted for throughout the trial.

Question 98: When a sponsor issues a protocol amendment that changes the risk profile for enrolled subjects, what step is mandatory before subjects continue participation?

A new randomization list must be generated before re-consent
Subjects must be re-consented using the updated informed consent form after IRB/IEC approval of the amendment (Correct answer)
The investigator may proceed and inform subjects at the next scheduled visit
The DSMB must approve the amendment before IRB review

Correct answer: Subjects must be re-consented using the updated informed consent form after IRB/IEC approval of the amendment

Material changes to risk require IRB/IEC review and approval of an updated consent form, after which enrolled subjects must be re-consented before continuing.

Question 99: Which of the following scenarios represents a violation of data integrity principles?

Querying a site to confirm a value that appears outside normal range
Entering a subject's weight from a clinic scale printout into the eCRF
Pre-dating a CRF entry to match the date a procedure was supposed to have occurred (Correct answer)
Documenting a missed assessment as 'not done' with a reason

Correct answer: Pre-dating a CRF entry to match the date a procedure was supposed to have occurred

Pre-dating entries to match a scheduled procedure date rather than the actual date of entry violates the 'contemporaneous' and 'attributable' requirements of ALCOA and constitutes data falsification.

Question 100: What is a Suspected Unexpected Serious Adverse Reaction (SUSAR)?

Any adverse event occurring during a Phase I trial
A safety event reported by the control group only
A serious adverse reaction that is both unexpected (not in the IB) and at least possibly related to the investigational product (Correct answer)
An adverse event that resolves without medical intervention

Correct answer: A serious adverse reaction that is both unexpected (not in the IB) and at least possibly related to the investigational product

A SUSAR is a serious adverse reaction that is unexpected (not described in the Investigator's Brochure) and for which there is a reasonable possibility of a causal relationship with the investigational product.

Clinical Trial Associate (CTA) Certification Exam

The CTA certification validates foundational knowledge and skills required for entry-level roles in clinical research, focusing on the operational aspects of clinical trials.

100

Questions

120 min

Time Limit

70%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds